SCHEMBL23405473

SCHEMBL23405473

COc1ccc(-n2nnc(-c3ccccc3)c2N)cc1OC

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
POLB P06746 2/20 0.54
NPC1 O15118 2/20 0.51
RAB9A P51151 2/20 0.51
TP53 P04637 2/20 0.51
MEN1 O00255 1/20 0.51
KMT2A Q03164 1/20 0.51
DHODH Q02127 1/20 0.51
ALDH1A1 P00352 3/20 0.48
MAPT P10636 2/20 0.48
HPGDS O60760 1/20 0.48
GAA P10253 1/20 0.48
SMN1; SMN2 Q16637 2/20 0.47
L3MBTL1 Q9Y468 1/20 0.46
ADORA1 P30542 1/20 0.45
GABRA2 P47869 1/20 0.44
GABRB2 P47870 1/20 0.44
PDE4A P27815 1/20 0.41
PDE4B Q07343 1/20 0.41
PDE4C Q08493 1/20 0.41
PDE4D Q08499 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23405497 0.87 POLB (0.62) POLBNPC1RAB9ATP53MEN1
SCHEMBL23405486 0.78 MAPT (0.55) POLBNPC1RAB9ATP53MEN1
SCHEMBL543832 0.77 NPC1 (0.78) POLBNPC1RAB9ATP53MEN1
SCHEMBL23405480 0.76 NPC1 (0.55) POLBNPC1RAB9ATP53MEN1
SCHEMBL14132957 0.74 NPC1 (0.63) POLBNPC1RAB9ATP53MEN1
SCHEMBL13735225 0.70 MAPK9 (0.51) NPC1RAB9AMEN1KMT2AALDH1A1
SCHEMBL27662257 0.69 L3MBTL1 (0.47) NPC1RAB9AALDH1A1MAPTGAA
SCHEMBL6774360 0.68 MAPK14 (0.49) POLBDHODH
SCHEMBL8229306 0.68 ALDH1A1 (0.48) NPC1RAB9ATP53MEN1KMT2A
SCHEMBL548302 0.66 POLB (0.69) POLBNPC1RAB9ATP53MEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12297178-B2 Triazole derivative and use thereof GYEONGGIDO BUSINESS & SCIENCE ACCELERATOR (KR) 2025-05-13 US claimed
US-20240166611-A1 TRIAZOLE DERIVATIVE AND USE THEREOF GYEONGGIDO BUSINESS & SCIENCE ACCELERATOR (KR) 2024-05-23 US claimed
US-20210163425-A1 TRIAZOLE DERIVATIVE AND USE THEREOF GYEONGGIDO BUSINESS & SCIENCE ACCELERATOR (KR) 2021-06-03 US claimed
US-12297178-B2 Triazole derivative and use thereof GYEONGGIDO BUSINESS & SCIENCE ACCELERATOR (KR) 2025-05-13 US disclosed
US-20240166611-A1 TRIAZOLE DERIVATIVE AND USE THEREOF GYEONGGIDO BUSINESS & SCIENCE ACCELERATOR (KR) 2024-05-23 US disclosed
US-20210163425-A1 TRIAZOLE DERIVATIVE AND USE THEREOF GYEONGGIDO BUSINESS & SCIENCE ACCELERATOR (KR) 2021-06-03 US disclosed
US-20210163425-A1 TRIAZOLE DERIVATIVE AND USE THEREOF GYEONGGIDO BUSINESS & SCIENCE ACCELERATOR (KR) 2021-06-03 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20210163425-A1 TRIAZOLE DERIVATIVE AND USE THEREOF FABP4, LIPC, GPR119 POLB 4310/4885NPC1 895/4885RAB9A 2452/4885
US-12297178-B2 Triazole derivative and use thereof FABP4, LIPC, GPR119 POLB 4363/4885NPC1 910/4885RAB9A 2503/4885
US-20240166611-A1 TRIAZOLE DERIVATIVE AND USE THEREOF FABP4, LIPC, GPR119 POLB 4363/4885NPC1 910/4885RAB9A 2503/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.